Squarepoint’s Matinas BioPharma MTNB Stock Holding History

Squarepoint’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,373	Closed	-$72.9K	–	5344
2024 Q3	$72.9K	Buy	+1,373	New	+$131K	﹤0.01%	3936
2023 Q4	–	Sell	-197	Closed	-$19.2K	–	4314
2023 Q3	$19.2K	Buy	+197	New	+$36.3K	﹤0.01%	3700
2021 Q3	–	Sell	-21	Closed	-$12K	–	3239
2021 Q2	$12K	Sell	21 -496	-96%	-$320K	﹤0.01%	3153
2021 Q1	$407K	Buy	517 +300	+138%	+$302K	﹤0.01%	2177
2020 Q4	$221K	Buy	+217	New	+$151K	﹤0.01%	2444
2019 Q1	–	Sell	-47	Closed	-$21K	–	2334
2018 Q4	$21K	Buy	+47	New	+$27.7K	﹤0.01%	1868

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Holos Integrated Wealth Kennett Square, Pennsylvania $223M AUM 9.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Squarepoint's MTNB Position: Q4 2024 in Review

Squarepoint sold out of Matinas BioPharma (MTNB) in Q4 2024, closing a stake of 1,373 shares — an estimated $72.9K sold.

Squarepoint first reported a position in MTNB in Q4 2018 and held it in 6 quarters. The position peaked at $407K in Q1 2021. 20 funds tracked by Wall St. Rank hold MTNB as of Q4 2024.

Squarepoint reported no remaining Matinas BioPharma position as of Q4 2024 after selling out during the quarter.
Squarepoint sold 1,373 Matinas BioPharma shares in Q4 2024, an estimated $72.9K.
Squarepoint first reported a position in Matinas BioPharma in Q4 2018 and held it in 6 quarters.
Squarepoint's Matinas BioPharma position peaked at $407K in Q1 2021.
20 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2024.

Based on Squarepoint's 13F filing for Q4 2024, filed 14 Feb 2025.